Physician profile
Annie Yan
NPI 1679203442
$6,215.09
in general payments reported to CMS, 2019-2025
19 companies · $1,887 in 2025
The $1,887 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $309 · 2023: $713 · 2024: $3,306 · 2025: $1,887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,726 · Travel and Lodging: $1,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,725.78 |
| Travel and Lodging | $1,180.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,801.01 | 2022-2025 | Envista Mx60 Iol, Stellaris Elite, Crystalens Accommodating Iol (At-52ao) |
| Alcon Vision LLC | $1,177.08 | 2023-2025 | Clareon, Unity, Hydrus Microstent |
| Abbvie INC. | $674.73 | 2023-2025 | Xen Glaucoma Treatment System |
| Johnson & Johnson Surgical Vision, INC. | $422.40 | 2022-2025 | Tecnis Iol, Tecnis Iol, Catalys System |
| Glaukos Corporation | $293.70 | 2024-2025 | Idose, Idosetr, Istent Infinite |
| Carl Zeiss Meditec USA, INC. | $279.97 | 2023-2025 | Quatera 700, Forum |
| Dompe US, INC. | $221.51 | 2025 | Oxervate |
| Harrow Eye, LLC | $204.19 | 2024-2025 | Verkazia, Natacyn, Flarex |
| Amgen INC. | $168.11 | 2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $152.47 | 2024 | |
| Genentech USA, INC. | $124.99 | 2023 | Vabysmo |
| Recordati_rare_diseases_inc. | $123.98 | 2025 | Cystadrops |
| Axogen | $121.29 | 2023 | Avance Nerve Graft |
| Sun Pharmaceutical Industries INC. | $119.21 | 2024 | |
| Horizon Therapeutics Plc | $111.57 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $98.68 | 2024 | Izervay |
| Sight Sciences, INC. | $76.95 | 2025 | Omni Surgical System, Sion Surgical Instrument |
| Rayner Intraocular Lenses Limited | $26.56 | 2025 | Omidria |
| New World Medical,INC. | $16.69 | 2025 | Via360, Streamline, Kahook Dual Blade |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annie Yan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.